Eli Lilly & Co. (LLY) to Release Quarterly Earnings on Wednesday
Eli Lilly & Co. (NYSE:LLY) is set to announce its Q313 earnings results on Wednesday, October 23rd. Analysts expect the company to announce earnings of $1.04 per share and revenue of $5.76 billion for the quarter. Eli Lilly & Co. has set its FY13 guidance at $4.05-4.15 EPS.
Eli Lilly & Co. (NYSE:LLY) last issued its quarterly earnings data on Wednesday, July 24th. The company reported $1.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.15. The company had revenue of $5.93 billion for the quarter, compared to the consensus estimate of $5.82 billion. During the same quarter in the previous year, the company posted $0.83 earnings per share. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. On average, analysts expect Eli Lilly & Co. to post $4.14 EPS for the current fiscal year and $2.76 EPS for the next fiscal year.
Shares of Eli Lilly & Co. (NYSE:LLY) traded up 1.33% on Tuesday, hitting $50.31. The stock had a trading volume of 3,474,553 shares. Eli Lilly & Co. has a 1-year low of $44.88 and a 1-year high of $58.40. The stock’s 50-day moving average is $51.07 and its 200-day moving average is $52.81. The company has a market cap of $54.345 billion and a P/E ratio of 11.15.
The company also recently announced a quarterly dividend, which is scheduled for Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a dividend of $0.49 per share. This represents a $1.96 annualized dividend and a dividend yield of 3.95%.
Several analysts have recently commented on the stock. Analysts at Jefferies Group downgraded shares of Eli Lilly & Co. from a “hold” rating to an “underperform” rating in a research note to investors on Friday, October 11th. They now have a $40.00 price target on the stock, down previously from $49.00. On the ratings front, analysts at Edward Jones upgraded shares of Eli Lilly & Co. from a “sell” rating to a “hold” rating in a research note to investors on Thursday, October 10th. Finally, analysts at Credit Suisse initiated coverage on shares of Eli Lilly & Co. in a research note to investors on Tuesday, October 8th. They set a “neutral” rating on the stock. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $55.53.
Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.